Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The FDA's support marks a pivotal step for Lantern Pharma as it refines its clinical development strategy for LP-300. The HARMONIC trial is evaluating LP-300 in combination with standard chemotherapy in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. The amended protocol narrows the focus to patients with the specific EGFR exon 21 L858R mutation, a subset where LP-300's unique mechanism of action may provide enhanced efficacy. This precision approach aligns with Lantern's broader strategy of leveraging its proprietary RADR platform to identify patient populations most likely to benefit from its therapies.
Lantern Pharma is a clinical-stage precision oncology company that uses artificial intelligence and machine learning to transform cancer therapy development. Its pipeline includes LP-184, LP-284, and LP-300, the latter being the focus of the HARMONIC trial. The company also has a wholly owned CNS-focused subsidiary, Starlight Therapeutics, developing LP-184 for pediatric CNS cancers. Additionally, Lantern recently made its multi-agentic AI co-scientist platform, withZeta.ai, commercially available as a subscription-based research platform, generating a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The FDA's non-objection to the protocol amendments reduces regulatory uncertainty for Lantern Pharma and could expedite the clinical development timeline for LP-300. For never-smoker lung cancer patients with specific EGFR mutations, who often have limited options after TKI failure, LP-300 represents a potential new treatment avenue. The company's focus on biomarker-driven patient selection may also increase the likelihood of trial success, as it targets a population with a higher probability of response. This regulatory milestone underscores the growing importance of precision medicine in oncology and Lantern's commitment to using AI to identify and develop targeted therapies.
